Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia

Journal of Hospital Infection

Volumn 59, Issue 1, 2005, Pages 27-32

  Roghmann, M ^a,c,e   Taylor, K L ^b   Gupte, A ^b   Zhan, M ^c   Johnson, J A ^a,c   Cross, A ^d   Edelman, R ^d   Fattom, A I ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Nabi Biopharmaceuticals   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

^e NONE   (United States)

Author keywords

Bacteraemia; Capsular serotyping; Immunotherapy; Methicillin resistance; Staphylococcus aureus

Indexed keywords

BACTERIAL POLYSACCHARIDE; METICILLIN; POLYCLONAL ANTIBODY;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; SEROPREVALENCE; SEROTYPE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE; UNITED STATES;

BACTEREMIA; BACTERIAL CAPSULES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DIABETES COMPLICATIONS; EPIDEMIOLOGY, MOLECULAR; FEMALE; HOSPITALS, VETERANS; HUMANS; INFECTION CONTROL; KIDNEY FAILURE, CHRONIC; MALE; MARYLAND; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYSACCHARIDES, BACTERIAL; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTYPING; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 10244234203     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2004.07.014     Document Type: Article

References (15)

1. P.G. Welch A. Fattom J. Moore Jr et al. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis J Am Soc Nephrol 7 1996 247-253
2. A.I. Fattom J. Sarwar A. Ortiz R. Naso A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge Infect Immun 64 1996 1659-1665
3. H. Shinefield S. Black A. Fattom et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis N Engl J Med 346 2002 491-496
4. J.C. Lee J.S. Park S.E. Shepherd V. Carey A. Fattom Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats Infect Immun 65 1997 4146-4151
5. T. Na'was A. Hawwari E. Hendrix et al. Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients J Clin Microbiol 36 1998 414-420
6. T. Essawi T. Na'was A. Hawwari S. Wadi A. Doudin A.I. Fattom Molecular, antibiogram and serological typing of Staphylococcus aureus isolates recovered from Al-Makased Hospital in East Jerusalem Trop Med Int Health 3 1998 576-583
7. R.D. Arbeit W.W. Karakawa W.F. Vann J.B. Robbins Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus Diagn Microbiol Infect Dis 2 1984 85-91
8. D. Sompolinsky Z. Samra W.W. Karakawa W.F. Vann R. Schneerson Z. Malik Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types J Clin Microbiol 22 1985 828-834
9. J.M. Fournier A. Bouvet A. Boutonnier Predominance of capsular polysaccharide type 5 among oxacillin-resistant Staphylococcus aureus J Clin Microbiol 25 1987 1932-1933
10. H.K. Hochkeppel D.G. Braun W. Vischer Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8 J Clin Microbiol 25 1987 526-530
11. CDC. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000;28:429-448.
12. A. Fattom R. Schneerson S.C. Szu et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A Infect Immun 58 1990 2367-2374
13. A. Fattom R. Schneerson D.C. Watson et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A Infect Immun 61 1993 1023-1032
14. J.S. Garner W.R. Jarvis T.G. Emori T.C. Horan J.M. Hughes CDC definitions for nosocomial infections Am J Infect Control 16 1988 128-140
15. A. Guidry A. Fattom A. Patel C. O'Brien S. Shepherd J. Lohuis Serotyping scheme for Staphylococcus aureus isolated from cows with mastitis Am J Vet Res 59 1998 1537-1539